{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:09:50Z","timestamp":1785179390705,"version":"3.55.0"},"reference-count":64,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TauRx Therapeutics Ltd., Singapore","award":["PAR1577"],"award-info":[{"award-number":["PAR1577"]}]},{"name":"TauRx Therapeutics Ltd., Singapore","award":["PAR2074"],"award-info":[{"award-number":["PAR2074"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Background: The protective Icelandic mutation in the amyloid precursor protein (APP) gene, APPA673T, identified in Icelandic and other Nordic populations is associated with a significantly lower risk of developing Alzheimer\u2019s disease (AD). Conflicting results have been reported for the human APPA673T mutation in various knock-in models of AD, but the effect of the mouse APPA673T form in 5\u00d7 familial AD (5\u00d7FAD) mice has never been investigated. Methods: We crossed C57Bl6\/J mice expressing a single point mutation edited into the murine APP gene via Clustered Regularly Interspaced Short Palindromic Repeats\u2013CRISPR-associated (CRISPR-Cas) gene editing, termed mAPPA673T, with 5\u00d7FAD mice that overexpress human APP carrying the Swedish (K670N\/M671L), Florida (I716V), and London (V717I) mutations as well as human presenilin-1 (PS1) with two mutations (M146L and L286V); the resulting mice were termed 5\u00d7FAD \u00d7 mAPPA673T mice. We investigated amyloid beta-protein (A\u03b2) pathology in 5\u00d7FAD \u00d7 mAPPA673T, 5\u00d7FAD and their respective controls, mAPPA673T, and C57Bl6\/J wild type mice, at 6-months of age using immunohistochemistry, immunoblotting, and enzyme-linked immunosorbent assay (ELISA). Results: We found a moderate yet significant reduction in A\u03b2 plaque size in male 5\u00d7FAD \u00d7 mAPPA673T compared with 5\u00d7FAD mice. No differences were observed for soluble\/insoluble A\u03b240 and A\u03b242 levels per se, but lower plaque count\/area was found in 5\u00d7FAD \u00d7 mAPPA673T mice when A\u03b242\/A\u03b240 ratios were low, suggesting a genotype-dependent sensitivity to A\u03b2 aggregation and accumulation. Conclusions: The mAPPA673T mutation has the potential to modify A\u03b2 pathology in 5\u00d7FAD mice at the age of 6 months.<\/jats:p>","DOI":"10.31083\/jin48581","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:53:12Z","timestamp":1769687592000},"source":"Crossref","is-referenced-by-count":1,"title":["The Icelandic Mutation in the Murine APP Gene, mAPPA673T, on Amyloid-\u03b2 Plaque Burden in the 5\u00d7FAD Alzheimer Model"],"prefix":"10.31083","volume":"25","author":[{"given":"Anne","family":"Anschuetz","sequence":"first","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renny","family":"Listyono","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vorley","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Platt","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Harrington","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, UK"},{"name":"TauRx Therapeutics Ltd., AB24 5RP Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-6281","authenticated-orcid":true,"given":"Gernot","family":"Riedel","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7063-7136","authenticated-orcid":true,"given":"Karima","family":"Schwab","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Scott KR, Barrett AM. Dementia syndromes: evaluation and treatment. Expert Review of Neurotherapeutics. 2007; 7: 407\u2013422.","DOI":"10.1586\/14737175.7.4.407"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet. Public Health. 2022; 7: e105\u2013e125.","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"ref3","unstructured":"Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift Fur Psychiatrie Und Psychischgerichtliche Medizin 1907; 64: 146\u2013148. (In German)"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, et al. Interaction between A\u03b2 and Tau in the Pathogenesis of Alzheimer\u2019s Disease. International Journal of Biological Sciences. 2021; 17: 2181\u20132192.","DOI":"10.7150\/ijbs.57078"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Cho Y, Bae HG, Okun E, Arumugam TV, Jo DG. Physiology and pharmacology of amyloid precursor protein. Pharmacology & Therapeutics. 2022; 235: 108122.","DOI":"10.1016\/j.pharmthera.2022.108122"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Gabriele RMC, Abel E, Fox NC, Wray S, Arber C. Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities. Frontiers in Neuroscience. 2022; 16: 835645.","DOI":"10.3389\/fnins.2022.835645"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 330\u2013335.","DOI":"10.1073\/pnas.222681699"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer\u2019s disease. Biochimica et Biophysica Acta. 2000; 1502: 172\u2013187.","DOI":"10.1016\/s0925-4439(00)00043-0"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al. Neurotoxicity of Alzheimer\u2019s disease A\u03b2 peptides is induced by small changes in the A\u03b242 to A\u03b240 ratio. The EMBO Journal. 2010; 29: 3408\u20133420.","DOI":"10.1038\/emboj.2010.211"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nature Medicine. 1996; 2: 864\u2013870.","DOI":"10.1038\/nm0896-864"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America. 1991; 88: 7552\u20137556.","DOI":"10.1073\/pnas.88.17.7552"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 1968; 16: 673\u2013677.","DOI":"10.1177\/16.11.673"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Glenner GG, Wong CW. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications. 1984; 120: 885\u2013890.","DOI":"10.1016\/s0006-291x(84)80190-4"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Glenner GG, Wong CW. Alzheimer\u2019s disease and Down\u2019s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research Communications. 1984; 122: 1131\u20131135.","DOI":"10.1016\/0006-291x(84)91209-9"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987; 325: 733\u2013736.","DOI":"10.1038\/325733a0"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1985; 82: 4245\u20134249.","DOI":"10.1073\/pnas.82.12.4245"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Tcw J, Goate AM. Genetics of \u03b2-Amyloid Precursor Protein in Alzheimer\u2019s Disease. Cold Spring Harbor Perspectives in Medicine. 2017; 7: a024539.","DOI":"10.1101\/cshperspect.a024539"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012; 488: 96\u201399.","DOI":"10.1038\/nature11283"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Martiskainen H, Herukka SK, Stan\u010d\u00e1kov\u00e1 A, Paananen J, Soininen H, Kuusisto J, et al. Decreased plasma \u03b2-amyloid in the Alzheimer\u2019s disease APP A673T variant carriers. Annals of Neurology. 2017; 82: 128\u2013132.","DOI":"10.1002\/ana.24969"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Xia Q, Yang X, Shi J, Liu Z, Peng Y, Wang W, et al. The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer\u2019s Disease. Molecular Neurobiology. 2021; 58: 4038\u20134050.","DOI":"10.1007\/s12035-021-02385-y"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2006; 26: 10129\u201310140.","DOI":"10.1523\/JNEUROSCI.1202-06.2006"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Forner S, Kawauchi S, Balderrama-Gutierrez G, Kram\u00e1r EA, Matheos DP, Phan J, et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer\u2019s disease. Scientific Data. 2021; 8: 270.","DOI":"10.1038\/s41597-021-01054-y"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A\u03b2 aggregation in the 5XFAD mouse model of Alzheimer\u2019s disease. Neurobiology of Aging. 2012; 33: 196.e29\u201340.","DOI":"10.1016\/j.neurobiolaging.2010.05.027"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Oblak AL, Lin PB, Kotredes KP, Pandey RS, Garceau D, Williams HM, et al. Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study. Frontiers in Aging Neuroscience. 2021; 13: 713726.","DOI":"10.3389\/fnagi.2021.713726"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Sil A, Erfani A, Lamb N, Copland R, Riedel G, Platt B. Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model. Journal of Alzheimer\u2019s Disease: JAD. 2022; 85: 755\u2013778.","DOI":"10.3233\/JAD-210523"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Anschuetz A, Schwab K, Harrington CR, Wischik CM, Riedel G. Proteomic and non-proteomic changes of presynaptic proteins in animal models of Alzheimer\u2019s disease: A meta-analysis 2015-2023. Journal of Alzheimer\u2019s Disease: JAD. 2025; 107: 452\u2013476.","DOI":"10.1177\/13872877251362212"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Jang H, Lee S, Kim YJ, Lee J, Kim SW, Son Y, et al. Progressive Hippocampal Neuroarchitecture Changes in the 5\u00d7FAD Alzheimer\u2019s Disease Mouse Model. Journal of Integrative Neuroscience. 2025; 24: 40831.","DOI":"10.31083\/JIN40831"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Kokawa A, Ishihara S, Fujiwara H, Nobuhara M, Iwata M, Ihara Y, et al. The A673T mutation in the amyloid precursor protein reduces the production of \u03b2-amyloid protein from its \u03b2-carboxyl terminal fragment in cells. Acta Neuropathologica Communications. 2015; 3: 66.","DOI":"10.1186\/s40478-015-0247-6"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. The Journal of Biological Chemistry. 2014; 289: 30990\u201331000.","DOI":"10.1074\/jbc.M114.589069"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Wittrahm R, Takalo M, Kuulasmaa T, M\u00e4kinen PM, M\u00e4kinen P, Kon\u010darevi\u0107 S, et al. Protective Alzheimer\u2019s disease-associated APP A673T variant predominantly decreases sAPP\u03b2 levels in cerebrospinal fluid and 2D\/3D cell culture models. Neurobiology of Disease. 2023; 182: 106140.","DOI":"10.1016\/j.nbd.2023.106140"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"C\u00e9lestine M, Jacquier-Sarlin M, Borel E, Petit F, Lante F, Bousset L, et al. Transmissible long-term neuroprotective and pro-cognitive effects of 1-42 beta-amyloid with A2T icelandic mutation in an Alzheimer\u2019s disease mouse model. Molecular Psychiatry. 2024; 29: 3707\u20133721.","DOI":"10.1038\/s41380-024-02611-8"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Shimohama S, Fujioka R, Mihira N, Sekiguchi M, Sartori L, Joho D, et al. The Icelandic Mutation (APP-A673T) Is Protective against Amyloid Pathology In Vivo. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2024; 44: e0223242024.","DOI":"10.1523\/JNEUROSCI.0223-24.2024"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Tambini MD, Norris KA, D\u2019Adamio L. Opposite changes in APP processing and human A\u03b2 levels in rats carrying either a protective or a pathogenic APP mutation. eLife. 2020; 9: e52612.","DOI":"10.7554\/eLife.52612"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Mahler J, Morales-Corraliza J, Stolz J, Skodras A, Radde R, Duma CC, et al. Endogenous murine A\u03b2 increases amyloid deposition in APP23 but not in APPPS1 transgenic mice. Neurobiology of Aging. 2015; 36: 2241\u20132247.","DOI":"10.1016\/j.neurobiolaging.2015.03.011"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 2020; 40: 1769\u20131777.","DOI":"10.1177\/0271678X20943823"},{"key":"ref36","unstructured":"Paxinos G, Franklin K. The Mouse Brain in Stereotaxic Coordinates. 5th edn. Academic Press: Cambridge, Massachusetts, USA. 2019."},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Lemke N, Melis V, Lauer D, Magbagbeolu M, Neumann B, Harrington CR, et al. Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia. The Journal of Biological Chemistry. 2020; 295: 18508\u201318523.","DOI":"10.1074\/jbc.RA120.014890"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C, et al. ilastik: interactive machine learning for (bio)image analysis. Nature Methods. 2019; 16: 1226\u20131232.","DOI":"10.1038\/s41592-019-0582-9"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nature Methods. 2012; 9: 676\u2013682.","DOI":"10.1038\/nmeth.2019"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Jennrich RI. An Asymptotic \u03c72 Test for the Equality of Two Correlation Matrices. Journal of the American Statistical Association. 1970; 65: 904\u2013912.","DOI":"10.1080\/01621459.1970.10481133"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Serneels L, T\u2019Syen D, Perez-Benito L, Theys T, Holt MG, De Strooper B. Modeling the \u03b2-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer\u2019s disease. Molecular Neurodegeneration. 2020; 15: 60.","DOI":"10.1186\/s13024-020-00399-z"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease. Molecular Psychiatry. 2021; 26: 5481\u20135503.","DOI":"10.1038\/s41380-021-01249-0"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Guyon A, Rousseau J, Lamothe G, Tremblay JP. The protective mutation A673T in amyloid precursor protein gene decreases A\u03b2 peptides production for 14 forms of Familial Alzheimer\u2019s Disease in SH-SY5Y cells. PloS One. 2020; 15: e0237122.","DOI":"10.1371\/journal.pone.0237122"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Andersson E, Lindblom N, Janelidze S, Salvad\u00f3 G, Gkanatsiou E, S\u00f6derberg L, et al. Soluble cerebral A\u03b2 protofibrils link A\u03b2 plaque pathology to changes in CSF A\u03b242\/A\u03b240 ratios, neurofilament light and tau in Alzheimer\u2019s disease model mice. Nature Aging. 2025; 5: 366\u2013375.","DOI":"10.1038\/s43587-025-00810-8"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Blennow K, Zetterberg H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. Journal of Internal Medicine. 2018; 284: 643\u2013663.","DOI":"10.1111\/joim.12816"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Anschuetz A, Robinson L, Mondesir M, Melis V, Platt B, Harrington CR, et al. The effect of the Icelandic mutation APPA673T in the line 66 model of tauopathy. Biomolecules. 2026; 16: 28","DOI":"10.3390\/biom16010028"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Pluci\u0144ska K, Crouch B, Koss D, Robinson L, Siebrecht M, Riedel G, et al. Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2014; 34: 10710\u201310728.","DOI":"10.1523\/JNEUROSCI.0433-14.2014"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, et al. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. The Journal of Biological Chemistry. 2007; 282: 22707\u201322720.","DOI":"10.1074\/jbc.M611050200"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, et al. Co-localization of amyloid beta and tau pathology in Alzheimer\u2019s disease synaptosomes. The American Journal of Pathology. 2008; 172: 1683\u20131692.","DOI":"10.2353\/ajpath.2008.070829"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Henkins KM, Sokolow S, Miller CA, Vinters HV, Poon WW, Cornwell LB, et al. Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer\u2019s cortical synapses. Brain Pathology (Zurich, Switzerland). 2012; 22: 826\u2013833.","DOI":"10.1111\/j.1750-3639.2012.00598.x"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kurucu H, Colom-Cadena M, Davies C, Wilkins L, King D, Rose J, et al. Inhibitory synapse loss and accumulation of amyloid beta in inhibitory presynaptic terminals in Alzheimer\u2019s disease. European Journal of Neurology. 2022; 29: 1311\u20131323.","DOI":"10.1111\/ene.15043"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Sokolow S, Luu SH, Nandy K, Miller CA, Vinters HV, Poon WW, et al. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer\u2019s disease cortex. Neurobiology of Disease. 2012; 45: 381\u2013387.","DOI":"10.1016\/j.nbd.2011.08.027"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Tai HC, Wang BY, Serrano-Pozo A, Frosch MP, Spires-Jones TL, Hyman BT. Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer\u2019s disease. Acta Neuropathologica Communications. 2014; 2: 146.","DOI":"10.1186\/s40478-014-0146-2"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"H\u00e9raud C, Goufak D, Ando K, Leroy K, Suain V, Yilmaz Z, et al. Increased misfolding and truncation of tau in APP\/PS1\/tau transgenic mice compared to mutant tau mice. Neurobiology of Disease. 2014; 62: 100\u2013112.","DOI":"10.1016\/j.nbd.2013.09.010"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer\u2019s disease reveals selective molecular vesicular machinery vulnerability. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2016; 12: 633\u2013644.","DOI":"10.1016\/j.jalz.2015.12.005"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease. Neuron. 2014; 82: 756\u2013771.","DOI":"10.1016\/j.neuron.2014.05.004"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Zhang H, Jiang X, Ma L, Wei W, Li Z, Chang S, et al. Role of A\u03b2 in Alzheimer\u2019s-related synaptic dysfunction. Frontiers in Cell and Developmental Biology. 2022; 10: 964075.","DOI":"10.3389\/fcell.2022.964075"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Anschuetz A, Schwab K, Harrington CR, Wischik CM, Riedel G. A Meta-Analysis on Presynaptic Changes in Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s Disease: JAD. 2024; 97: 145\u2013162.","DOI":"10.3233\/JAD-231034"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Jiang LX, Huang GD, Su F, Wang H, Zhang C, Yu X. Vortioxetine administration attenuates cognitive and synaptic deficits in 5\u00d7FAD mice. Psychopharmacology. 2020; 237: 1233\u20131243.","DOI":"10.1007\/s00213-020-05452-9"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Kim J, Kang S, Chang KA. Effect of cx-DHED on Abnormal Glucose Transporter Expression Induced by AD Pathologies in the 5xFAD Mouse Model. International Journal of Molecular Sciences. 2022; 23: 10602.","DOI":"10.3390\/ijms231810602"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Vasilopoulou F, Rodr\u00edguez-Ar\u00e9valo S, Bag\u00e1n A, Escolano C, Gri\u00f1\u00e1n-Ferr\u00e9 C, Pall\u00e0s M. Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer\u2019s disease mouse model: a comparative study with donepezil. British Journal of Pharmacology. 2021; 178: 3017\u20133033.","DOI":"10.1111\/bph.15478"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease. Human Molecular Genetics. 2010; 19: R12\u2013R20.","DOI":"10.1093\/hmg\/ddq160"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Eimer WA, Vassar R. Neuron loss in the 5XFAD mouse model of Alzheimer\u2019s disease correlates with intraneuronal A\u03b242 accumulation and Caspase-3 activation. Molecular Neurodegeneration. 2013; 8: 2.","DOI":"10.1186\/1750-1326-8-2"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Poon CH, Wong STN, Roy J, Wang Y, Chan HWH, Steinbusch H, et al. Sex Differences between Neuronal Loss and the Early Onset of Amyloid Deposits and Behavioral Consequences in 5xFAD Transgenic Mouse as a Model for Alzheimer\u2019s Disease. Cells. 2023; 12: 780.","DOI":"10.3390\/cells12050780"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/25\/1\/10.31083\/JIN48581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:53:38Z","timestamp":1769687618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/25\/1\/10.31083\/JIN48581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0219-6352(25)01063-0"],"URL":"https:\/\/doi.org\/10.31083\/jin48581","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"48581"}}